Cutaneous T Cell Lymphoma Clinical Trial
Official title:
Real World Experience With Mogamulizumab in the Treatment of Cutaneous T-cell Lymphoma: a Multicenter Observational Study
This study is designed to describe the clinical activity and safety profile of mogamulizumab at standard dose in the treatment of CTCL patients in real world setting
Mogamulizumab (anti-CCR4) has been recently approved and reimbursed in Italy for the treatment of Cutaneous T-cell lymphoma (CTCL) after 1 previous systemic treatment based on the favourable results of the MAVORIC clinical trial. To date, no real-world data on significant series of patients treated routinely with mogamulizumab in clinical practice are available. As real-life data are essential to confirm the preliminary evidence displayed in phase III trials, this study aims at describing the clinical activity and safety profile of mogamulizumab at standard dose in the treatment of CTCL patients in real world settings. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02546440 -
Study on Therapy With Dimethylfumarate (DMF) in Patients With Cutaneous T Cell Lymphoma (CTCL)
|
Phase 2 | |
| Recruiting |
NCT04014374 -
Post-authorization Safety Study of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Treated With Mogamulizumab
|
||
| Recruiting |
NCT03340155 -
Mechanisms of Action of Photo(Chemo)Therapy in Skin Diseases
|
N/A | |
| Active, not recruiting |
NCT01460914 -
Outcomes of Cutaneous T-Cell Lymphoma and Graft-Versus-Host Disease With Extracorporeal Photopheresis Treatment
|
||
| Completed |
NCT04955340 -
A Phase 1, Open-label Study of the Absorption, Metabolism, Excretion of [14C]-Resminostat
|
Phase 1 | |
| Recruiting |
NCT02539472 -
Early Diagnosis of Mycosis Fungoides
|
N/A | |
| Recruiting |
NCT05680558 -
Photopheresis in Early-stage Mycosis Fungoides
|
Phase 2 | |
| Recruiting |
NCT01132989 -
Open-label Pilot Study of Lenalidomide (Revlimid) as Adjuvant Treatment for Refractory Cutaneous T Cell Lymphoma
|
Phase 2 | |
| Recruiting |
NCT05414500 -
Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides
|
Phase 1 | |
| Terminated |
NCT01663571 -
STAT3 in T Cells: At The Crossroads of Inflammation and Cancer
|
||
| Active, not recruiting |
NCT02192021 -
Micro Needle Array-Doxorubicin (MNA-D) in Patients With Cutaneous T-cell Lymphoma (CTCL)
|
Phase 1 | |
| Recruiting |
NCT05781386 -
A Phase I Trial of SIM1811-03 in Subjects With Advanced Tumors
|
Phase 1 | |
| Active, not recruiting |
NCT02576496 -
Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies
|
Phase 1 | |
| Active, not recruiting |
NCT03775525 -
Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer
|
Phase 1 | |
| Withdrawn |
NCT03235869 -
Radiation Therapy Plus Durvalumab for Tumor-Stage Cutaneous T-Cell Lymphoma
|
Early Phase 1 | |
| Active, not recruiting |
NCT01396070 -
Pilot Study of Brentuximab Vedotin (SGN-35) in Patients With MF With Variable CD30 Expression Level
|
N/A | |
| Completed |
NCT01198665 -
RAD001 Combined With CHOP in Newly Diagnosed Peripheral T-cell Lymphomas
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03932279 -
Characterization of the Microbiome in Cutaneous T Cell Lymphoma
|
||
| Not yet recruiting |
NCT05728879 -
Characterization of the Microbiome in Cutaneous T Cell Lymphoma Skin Lesions Before and After Use of APR-TD011® (RLF-TD011®) Spray Solution
|
Early Phase 1 | |
| Completed |
NCT01569724 -
Carbohydrate Metabolism Disorder Frequency in Hypertriglyceridemia Induced by Bexarotene of Cutaneous T Cell Lymphoma
|
Phase 4 |